Stem cell therapy is at an early phase of development, but it can be a good future therapeutic strategy in immune-mediated renal disease. There is some experimental evidence in animal models of anti-GBM disease, where mesenchymal stem cells were usedwheres, which are progenitors of renal tissue. ]. A case of NCGN due to MPA successfully treated with stem cell therapy has been reported. The patient’s serum creatinine peaked at 690 µmol/L; standard therapy with cyclophosphamide and glucocorticoids was ineffective, and rituximab was not tolerated; following treatment with autologous mesenchymal stem cells, the patient’s creatinine came down to 168 µmol/L in parallel with a reduction in the ANCA titre.^[1]